Evidence map›Paper›PMID 35997582›Full record

ArticleHuman vaccines & immunotherapeutics2022

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.

Suzanne M Garland, Manjula Anagani, Neerja Bhatla, Sukanta Chatterjee, Sanjay Lalwani, Cecil Ross, Thomas Group, Jianxin Lin, Alain Luxembourg, Anuj Walia and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00380367 (Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00380367 phase3completednot on this map

Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2007 to 2008Enrolled110ConditionsPapillomavirus InfectionsArmsQuadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Suzanne M GarlandDepartment of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia.
Manjula AnaganiWoman and Child Institute, CARE Super Specialty Hospital & Transplant Centre, Hyderabad, India.
Neerja BhatlaDepartment of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
Sukanta ChatterjeeDepartment of Pediatrics, KPC Medical College & Hospital, Kolkata, India.
Sanjay LalwaniLalwani Mother & Child Care Hospital, Pune, India.
Cecil RossDepartment of Chest Medicine & Hematology, St. John's Medical College Hospital, Bangalore, India.
Thomas GroupMerck & Co., Inc., Rahway, NJ, USA.
Jianxin LinMerck & Co., Inc., Rahway, NJ, USA.
Alain LuxembourgMerck & Co., Inc., Rahway, NJ, USA.
Anuj WaliaMerck & Co., Inc., Rahway, NJ, USA.
Yingmei TuMerck & Co., Inc., Rahway, NJ, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USAll India Institute of Medical Sciences · INKPC Medical College and Hospital · INRoyal Women's Hospital · AUSt.John's Medical College Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three completed clinical trials in India: a single-arm study (V501-029 [NCT00380367]) in Indian girls (aged 9-15 years;

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesAdolescentAntibodies, ViralChildClinical Trials as TopicFemaleHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Human Papillomavirus VirusesHumansImmunogenicity, VaccineMaleVaccinationAntibodies, ViralHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus VaccinesClinical trialhuman papillomavirus vaccineimmunogenicityIndiasafety

Identifiers

PMID35997582
PMCPMC9746475
OpenAlexW4292722408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.